Helix Biopharma Corp. (TSE:HBP) has released an update.
Helix BioPharma Corp., a Toronto-based biopharmaceutical company specializing in immune-oncology therapies, has announced a private placement of approximately 12.8 million common shares at $0.15 each, aiming to raise CAD$1.915 million. The proceeds are intended for working capital, with the transaction contingent on customary closing conditions and regulatory approvals. The shares will undergo a standard four-month hold period, and a finder’s fee will be paid in connection with the offering.
For further insights into TSE:HBP stock, check out TipRanks’ Stock Analysis page.
